Alembic Pharmaceuticals limited reported it’s consolidated unaudited financial results for the fourth quarter and year ending 31st March, 2020.
Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said, “It was a remarkable year for the company where we recorded our highest revenue and profit ever. This was led by strong growth in the US generics business. During the fourth quarter we saw our India and rest of world (ROW) business also getting back to a robust growth.”
The board in it’s meeting held on 6th March, 2020 declared interim dividend on equity shares at Rs. 10.00 per share i.e. 500% for FY20.
For the fiscal year ended March 31, 2020, the consolidated net profit of the company rose to Rs 829.12 crore as against Rs 584.37 crore for the previous fiscal year.
Shares of Alembic Pharmaceuticals closed at Rs 698.55 per scrip on BSE, up 9.56 per cent from its previous close.